Get notified of page updates
Education > XRAY > Breast Cancer

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

Breast Cancer

81 through 90 of 260

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Guideline : FDA issues alert on a drug combination to treat triple-negative breast cancer

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with metastatic triple-negative breast cancer

The immunotherapy drug Tecentriq (atezolizumab) is approved for use with Abraxane (nab-paclitaxel) to treat metastatic triple-negative breast cancer. Tecentriq is NOT approved for use with Taxol (paclitaxel). The Food and Drug Administration has issued an alert to doctors, researchers and patients warning that Tecentriq should not be used in combination with Taxol to treat patients with advanced triple-negative breast cancer. (09/18/20)

Read More

Relevance: Medium-Low

Strength of Science: Medium-Low

Research Timeline: Human Research

View Related Clinical Trials

Study : Dairy milk may slightly raise breast cancer risk

Relevance: Medium-Low

Strength of Science: Medium-Low

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Women who consume dairy or soy

Debate continues about whether consuming soy or dairy products increases breast cancer risk. This study looked at a large number of women and found no link between soy and breast cancer risk. The study did find that postmenopausal women who drank dairy milk have a small increase in breast cancer risk. (09/04/20)

Read More

Relevance: High

Strength of Science: High

Quality of Writing: High

View Related Clinical Trials

Study : Among women with breast cancer, who should have genetic testing for an inherited mutation?

Relevance: High

Strength of Science: High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: Women diagnosed with breast cancer who do not know if they have an inherited mutation in a gene linked to breast cancer

Which breast cancer patients should consider genetic testing? Knowing whether you have an inherited mutation may inform the decisions you and your healthcare provider make about treatment. But it can also increase stress and anxiety. This XRAY reviews a study of how different guidelines affect genetic testing recommendations for people with breast cancer. (8/27/20)

Read More

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Study : Insulin resistance linked to differences in breast cancer survival between Black and White women

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Black women

Black women are more likely to die from breast cancer compared to White women. More Black women have a condition called insulin resistance than White women.  This study found that insulin resistance might be one of the reasons that Black women are more likely than White women to die from breast cancer. Additional research is needed to see if lowering insulin levels will improve breast cancer survival in Black women. (07/30/20)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Healthy romantic relationships may decrease stress and inflammation for breast cancer survivors

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Women with breast cancer who have romantic partners

Satisfying romantic relationships may improve outcomes for women with breast cancer. In a new study, women who were more satisfied with their romantic relationships experienced less stress and lower inflammation. This study suggests that decreasing stress may be beneficial for breast cancer survivors. (7/25/20)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with metastatic breast cancer with an inherited mutation in PALB2 or tumor with a BRCA mutation

Early results of a small study showed that women with metastatic breast cancer and an inherited  mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

Study : What is the risk for a new breast cancer diagnosis in the other breast for women with a BRCA1, BRCA2 or TP53 mutation?

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

Most relevant for: Women diagnosed with breast cancer who have a mutation in BRCA1, BRCA2 or TP53

For women who have been diagnosed with breast cancer, knowing their risk of breast cancer in the other (contralateral) breast can help them make decisions about surgery and screening. This study shows that women with an inherited mutation in BRCA1, BRCA2 or TP53 have an increased risk for contralateral breast cancer. This risk is highest in women with a TP53 mutation. (6/6/20)

Read More

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Update : FDA approves tucatinib (Tukysa) for metastatic Her2-positive breast cancer

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Patients with Her2-positive metastatic breast cancer

The FDA has approved the use of tucatinib (Tukysa) in combination with chemotherapy as a treatment for people with metastatic Her2-positive breast cancer. This  approval includes treatment of people whose breast cancer has spread to the brain. (4/29/20)

Read More

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Update : FDA approves new treatment for metastatic triple-negative breast cancer

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with metastatic triple-negative breast cancer who have received at least two prior lines of treatment

The FDA approved the use of sacituzumab govitecan-hizy (Trodelvy), a treatment drug for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. (4/27/20)

Read More

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Personal Story : Improving the quality of life for people with metastatic breast cancer

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: People diagnosed with metastatic breast cancer

Washington Post article described the cancer experience of a young woman living with metastatic breast cancer. It also highlights how integrative medicine and palliative care, including acupuncture, massage, yoga, pain management, mental health therapy and nutrition can improve quality of life for people with metastatic cancer. (3/10/20)

Este artículo está disponible en español.

Read More

This Portal Sponsored By:

Centers for Disease Control